Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253185 · ClinicalTrials.gov registry record · Phase 1
A Study of SC-007 in Subjects With Advanced Cancer
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03253185 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 7 participants.
The verdict
NCT03253185, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer.
Interventions
- DRUG SC-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2018-04-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03253185
The ClinicalTrials.gov registry entry for NCT03253185 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SC-007 is the first listed.
NCT03253185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03253185 about?
NCT03253185 is a clinical study titled "A Study of SC-007 in Subjects With Advanced Cancer". This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose e...
What is the current status of trial NCT03253185?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-09-13. Estimated completion is 2018-04-02.
What interventions are being tested in trial NCT03253185?
The interventions under investigation include: SC-007 (DRUG).
Who is sponsoring clinical trial NCT03253185?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.